NGM Reports Completion of Patient Enrollment in P-II CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

July 23, 2021 Auto Bot Clinical Trials 0

Shots:

  • The company has completed enrollment in the P-II CATALINA study evaluating the safety and efficacy of NGM621 (IVT injections, q4w/ q8w) vs sham control in 320 patients with geographic atrophy secondary to AMD. The results are expected in H2’22
  • The 1EPs of the P-II CATALINA study is the rate of change in geographic atrophy lesion area as measured by FAF imaging @52 wks. of treatment & will evaluate the incidence and severity of ocular and systemic AEs
  • Additionally, the P-I results demonstrate that the therapy was well-tolerated and had an acceptable safety profile. NGM621 is a mAb engineered to inhibit complement C3

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: NGM Biopharmaceuticals

The post NGM Reports Completion of Patient Enrollment in P-II CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration first appeared on PharmaShots.